{"id":"W3172937358","doi":"10.1200/jco.2021.39.15_suppl.4514","title":"Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Axitinib; Cabozantinib; Internal medicine; Oncology; Renal cell carcinoma; Everolimus; Regimen; Clinical trial; Interim analysis; Neutropenia; Sunitinib; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007248534,0.0001799739,0.0005656263,0.0002576745,0.0003675333,0.000783482,0.0003048251,0.000419841,0.0009161046],"category_scores_gemma":[0.000804512,0.0001238203,0.0007607518,0.0004350857,0.0002028227,0.0004784217,0.0005065437,0.0008363868,0.0001539841],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007559846,"about_ca_system_score_gemma":0.0005826928,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001398111,"about_ca_topic_score_gemma":0.002471493,"domain_scores_codex":[0.9996504,0.0000904091,0.00002998908,0.00008998485,0.00005031775,0.00008891022],"domain_scores_gemma":[0.9992198,0.0001028369,0.000295722,0.00004355213,0.00003940566,0.0002985723],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02244147,0.000943594,0.9472412,0.00007651031,0.0003792215,0.0004902194,0.0002194794,0.001189214,0.003320762,0.0001133129,0.0009843681,0.02260068],"study_design_scores_gemma":[0.001605573,0.01416529,0.9776375,0.00003113995,0.0004203389,0.001170369,0.0002184023,0.001642593,0.001071499,0.0001767412,0.001836637,0.00002399027],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9987863,0.0003148353,0.00004446366,0.00004642718,0.000005720575,0.00001785047,0.0004065546,0.000002584346,0.0003752552],"genre_scores_gemma":[0.9979634,0.0001002299,0.00005929903,0.00006686788,0.00001650873,0.00003042472,0.001522185,0.000001866581,0.0002391233],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001398111,"threshold_uncertainty_score":0.005485058,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1313786049399812,"score_gpt":0.4213184102139248,"score_spread":0.2899398052739436,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}